| August 2017 |
Official opening of the "Centre for Predictive Drug Discovery" laboratories in Glasgow, Scotland |
| May 2017 |
Alliance is formed with Fox Chase Medical Center (Philadelphia, U.S.A.) to accelerate biomarker and genetic discovery |
| November 2016 |
Agreement is signed with Steminent Biopharmaceuticals (Taiwan) for Stemchymal cell therapy technology; REPROCELL Medical business unit is created |
| November 2016 |
REPROCELL Europe founded with full-trading offices located at the Biopta site in Glasgow, Scotland (U.K.); Dr. David Bunton named CEO. |
| August 2016 |
REPROCELL USA founded with full-trading offices located at the BioServe site in Beltsville, MD (U.S.A.); Dr. Rama Modali named CEO. |
| November 2015 |
Acquired Biopta (Glasgow, Scotland, U.K.) |
| October 2014 |
REPROCELL USA, the Company’s affiliate in the U.S.A., acquired the business of iPS cell business department of Stemgent (U.S.A.), and changed its name to Stemgent. |
| September 2014 |
Acquired BioServe (Beltsville, MD, U.S.A.) |
| July 2014 |
Acquired Reinnervate (County Durham, England, U.K.) |
| February 2014 |
Consignment and entrustment agreement with Japan Blood Products Organization for the clinical laboratory measurement work. |
| February 2014 |
Establishment of RC Partners, Inc., which is the Company’s affiliate to invest in a general partner of the venture capital fund called “Cell Innovation Partners, L.P.” that focuses on the creation of next-generation pharmaceutical and medical businesses. |
| November 2013 |
Launch of custom-made disease model cells in collaboration with Takara Bio, Inc. (Cell products) |
| October 2013 |
Shin-Yokohama District (REPROCELL, Inc) was chosen as the Life Innovation Comprehensive Special Zones for International Competitiveness Development. |
| June 2013 |
Listed on the Osaka Securities Exchange JASDAQ Growth Market. |
| December 2012 |
Establishment of the sales office of REPROCELL USA Inc. in Boston. |
| October 2012 |
Professor Shinya Yamanaka of Kyoto University received the Nobel Prize in Physiology or Medicine. |
| August 2012 |
Establishment of agreement for sales collaboration concerning human iPS cells model for Alzheimer’s disease with PerkinElmer Japan Co., Ltd. |
| June 2012 |
Launch of human iPSC-derived neuron model cells for Alzheimer’s disease. |
| May 2012 |
Human iPSC-derived hepatocytes (ReproHepato) launch |
| October 2011 |
A new version of human iPSC-derived cardiomyocytes (ReproCardio2, frozen) launch |
| April 2011 |
A new feeder-free culture medium ReproFF2 launched |
| April 2011 |
REPROCELL USA, Ltd. established |
| October 2010 |
Human iPSC-derived DA neuron (ReproNeuro DA) launch |
| January 2010 |
The headquarters and laboratory have moved to Yokohama |
| April 2009 |
Human iPSC-derived cardiomyocytes (ReproCardio) and the assay service using it (QTempo) launch |
| August 2008 |
Cardiotoxicity testing (QTempo) using monkey ES cell-derived cardiomyocytes launch |
| July 2005 |
National granted project with Kyoto University and pharmaceutical companies “Drug screening and toxicity technology using human ES cells” (2005 to 2010) |
| June 2005 |
Laboratory installed in Tokyo |
| April 2005 |
Launch of research reagent business: Primate ES cell medium |
| August 2004 |
Start commercializing Nanog antibodies (human, mouse) |
| June 2003 |
Joint research agreement with Kyoto University |
| May 2003 |
Joint research agreement with Tokyo University |
| February 2003 |
REPROCELL Inc. Established |
![StemFit® Mesenchymal Stem Cell therapy for liver cirrhosis [INTERVIEW]](https://www.reprocell.com/hubfs/07AUG20%20liver%20organ%20human-1.jpeg)
